ME250117P1500
- 1.15
- 0.000.00%
23andMe Newsroom
23andMe Inches Higher on Hookup With Mirador
Express News | 23Andme and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation
Express News | GSK PLC Reports 9.5% Stake in 23Andme Holding as of Nov 12 Vs Previous Stake of 11.2% as of Feb 7 - SEC Filing
23andMe Shares Are Trading Lower. The Stock May Be Moving on Continued Weakness After Reporting a Q2 Revenue Miss Yesterday.
Express News | 23andMe Shares Are Trading Lower. The Stock May Be Moving on Continued Weakness After Reporting a Q2 Revenue Miss Yesterday
23andMe Reports Improved Financial Metrics Amid Revenue Decline
23andMe Holding Co. (ME) Q2 2025 Earnings Call Transcript Summary
23andMe Holding Co. (ME) Q2 2025 Earnings Call Transcript
23andMe Says There's Substantial Doubt It Can Stay in Business
23andMe Reports Sales Decline Day After Announcing Plans to Cut 40% of Workforce
23andMe | 8-K: 23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
23andMe Considers Raising Capital as It Keeps Burning Cash -- Market Talk
23andMe Lays Off 40% of Staff, Shuts Drug Development Business -- Update
23andMe | 10-Q: Q2 2025 Earnings Report
23andMe 2Q Loss Narrows After Disclosing Restructuring
23andMe Reports Q2 EPS ($2.32) Vs ($3.17) Last Year
Express News | 23andMe Holding Q2 2025 GAAP EPS $(2.32), Sales $44.071M Miss $54.300M Estimate
23andMe's Stock Turns Lower After Company Posts Its Latest Quarterly Loss
23andMe: Will Continue to Prioritize Driving Recurring Rev Through Our Subscription Business, in Addition to Growing Our Research Partnership Business as We Look to the Future >ME